Tim Perera

524 total citations
8 papers, 298 citations indexed

About

Tim Perera is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Tim Perera has authored 8 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Tim Perera's work include HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Tim Perera is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Tim Perera collaborates with scholars based in Italy, United Kingdom and Belgium. Tim Perera's co-authors include Peter King, Elena Ghiso, Silvia Giordano, J. Rafael Sierra, Laura Casorzo, Virna Cepero, Paolo M. Comoglio, Simona Corso, Peter J. Parker and Adrian L. Harris and has published in prestigious journals such as Cancer Research, PLoS Biology and Annals of Oncology.

In The Last Decade

Tim Perera

7 papers receiving 290 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tim Perera Italy	5	160	145	77	76	72	8	298
Ben Staal United States	9	219 1.4×	140 1.0×	62 0.8×	28 0.4×	55 0.8×	14	365
Anita Welk Germany	6	154 1.0×	175 1.2×	51 0.7×	24 0.3×	117 1.6×	7	321
Eri Taguchi Japan	7	219 1.4×	119 0.8×	95 1.2×	83 1.1×	18 0.3×	11	367
J. C. Bendell United States	13	261 1.6×	208 1.4×	82 1.1×	50 0.7×	29 0.4×	37	413
David Surguladze United States	10	212 1.3×	290 2.0×	89 1.2×	31 0.4×	17 0.2×	21	531
Meghan Nechrebecki United States	3	226 1.4×	404 2.8×	238 3.1×	116 1.5×	26 0.4×	4	542
Sara Zaghlul United States	5	300 1.9×	260 1.8×	127 1.6×	100 1.3×	17 0.2×	8	492
Megan M. Starr United States	4	181 1.1×	180 1.2×	98 1.3×	57 0.8×	10 0.1×	4	335
Frank Tsai United States	14	185 1.2×	278 1.9×	97 1.3×	41 0.5×	12 0.2×	36	483
Jens E. Ruhe Germany	5	247 1.5×	79 0.5×	35 0.5×	25 0.3×	24 0.3×	8	308

Countries citing papers authored by Tim Perera

Since Specialization

Citations

This map shows the geographic impact of Tim Perera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Perera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Perera more than expected).

Fields of papers citing papers by Tim Perera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Perera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Perera. The network helps show where Tim Perera may publish in the future.

Co-authorship network of co-authors of Tim Perera

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Perera. A scholar is included among the top collaborators of Tim Perera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Perera. Tim Perera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Perera, Tim, Peter de Bruijn, Rachel Galot, et al.. (2024). 143 (PB131): Preliminary Safety and Pharmacokinetics of the MET-TKI DO-2 in Patients with Advanced Solid Tumors Harboring MET Aberrations: A Phase I Study. European Journal of Cancer. 211. 114665–114665. 1 indexed citations

Cepero, Virna, J. Rafael Sierra, Simona Corso, et al.. (2010). MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors. Cancer Research. 70(19). 7580–7590. 141 indexed citations

Gijsen, Merel, P King, Tim Perera, et al.. (2010). UPREGULATION OF ADAM17 PROTEASE AND HER LIGANDS THROUGH A PKB NEGATIVE FEEDBACK LOOP MEDIATES ACQUIRED RESISTANCE TO TRASTUZUMAB IN HER2 OVEREXPRESSED BREAST CANCER. Annals of Oncology. 21. 51–51. 3 indexed citations

Gijsen, Merel, Peter King, Tim Perera, et al.. (2010). HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer. PLoS Biology. 8(12). e1000563–e1000563. 109 indexed citations

King, Peter, Tinne Verhulst, Richard H. Argent, et al.. (2010). Abstract 3628: JNJ-38877605: A selective oral Met inhibitor for the treatment of cancer. Cancer Research. 70(8_Supplement). 3628–3628. 4 indexed citations

Ghiso, Elena, Virna Cepero, J. Rafael Sierra, et al.. (2010). 312 MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. European Journal of Cancer Supplements. 8(7). 100–100. 6 indexed citations

Versele, Matthias, Willem Talloen, Peter King, et al.. (2009). Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout. Molecular Cancer Therapeutics. 8(7). 1846–1855. 33 indexed citations

Perera, Tim, Matthias Versele, Philip D. King, et al.. (2006). 588 POSTER JNJ-26483327 is a novel multi-targeted tyrosine kinase inhibitor with cellular activity against EGFR, Her2, Src and VEGFR3. European Journal of Cancer Supplements. 4(12). 178–178. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact